Ibrutinib continues strong showing against mantle cell lymphoma
In a major international study led by researchers at The University of
Texas MD Anderson Cancer Center, the targeted therapy ibrutinib
continues to show remarkable promise for the treatment of relapsed or
refractory mantle cell lymphoma (MCL).
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news